Compare AbbVie Inc (ABBV) vs Home Depot Inc (HD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Home Depot Inc — how do they compare? AbbVie Inc trades at $254.05 (market cap $449.91B), while Home Depot Inc trades at $336 (market cap $344.21B). The key difference: AbbVie Inc is the larger of the two by market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | HD | |
|---|---|---|
Market Cap | $449.91B | $344.21B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $423.42 |
52-Week Low | $184.85 | $297.51 |
Enterprise Value | $513.38B | $405.77B |
Dividend Yield | 2.72% | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Home Depot (HD) trades at $336.64, down 4.0% over the past day, reflecting near-term market pressures. The stock shows a bullish technical signal with moving averages supporting upside, while oscillators remain neutral. Fundamentally, revenue grew to $159.51B in 2025 with a net income margin of 8.41%, though margins have compressed from prior years. Recent earnings beat expectations in Q1 2026, but Q3 2025 missed estimates. The company maintains strong profitability with ROE at 128.38% and declared a $2.33 dividend payable in June 2026.
The outlook for HD is cautiously optimistic, supported by analyst consensus and Pro segment growth, but faces headwinds from weakening big-ticket demand and rising mortgage rates. With a consensus price target of $370.59 implying ~10% upside, the stock presents a value opportunity for long-term investors, though margin pressure and housing market volatility pose risks to near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →
